Intra-Cellular Therapies, Inc., a biopharmaceutical company, discovers and develops small molecule drugs for the treatment of neuropsychiatric and neurologic disorders within the central nervous system (CNS). Its lead drug candidate is ITI-007, which is in phase III clinical development for the treatment of schizophrenia, behavioral disturbances in dementia, bipolar disorder, depression…More, and other neuropsychiatric and neurological disorders.
Social Media Links
REPORT RATINGS
4.8 / 5.0 (162)
Intra-Cellular Therapies Inc reports have an aggregate usefulness score of 4.8 based on 162 reviews.